MENRIUM 5-4
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MENRIUM 5-4 (MENRIUM 5-4).
Combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an anticholinergic that blocks muscarinic acetylcholine receptors.
| Metabolism | Chlordiazepoxide: Hepatic via CYP3A4 and CYP2C19 to active metabolites (desmethylchlordiazepoxide, demoxepam); Clidinium: Hepatic, primarily oxidative pathways. |
| Excretion | Chlordiazepoxide: Renal excretion of unchanged drug (<1%) and conjugates (60-70%); fecal excretion (30-40%). Clidinium: Primarily renal elimination as unchanged drug and metabolites (50-70%), with biliary/fecal excretion (30-50%). |
| Half-life | Chlordiazepoxide: Terminal half-life 5-30 hours (mean 10 hours), extended to 30-60 hours in elderly or hepatic impairment. Clidinium: Terminal half-life approximately 1-2 hours due to rapid clearance. |
| Protein binding | Chlordiazepoxide: 96-98% bound to albumin. Clidinium: Approximately 50% bound to plasma proteins. |
| Volume of Distribution | Chlordiazepoxide: 0.26 L/kg. Clidinium: 0.5 L/kg. |
| Bioavailability | Chlordiazepoxide oral: 100% (complete). Clidinium oral: 5-30% (low due to first-pass metabolism, variable). |
| Onset of Action | Chlordiazepoxide oral: 30-60 minutes (anxiolytic). Clidinium oral: 1-2 hours (anticholinergic). |
| Duration of Action | Chlordiazepoxide: 6-8 hours (anxiolytic), up to 24 hours with accumulation. Clidinium: 3-4 hours (antispasmodic), requires multiple daily dosing. |
1 tablet (chlordiazepoxide 5 mg / clinidium bromide 2.5 mg) orally 3 to 4 times daily before meals and at bedtime. Maximum dose: 8 tablets per day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: administer 50% of usual dose. GFR <30 mL/min: avoid use due to accumulation of chlordiazepoxide active metabolites. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: contraindicated due to impaired chlordiazepoxide metabolism. |
| Pediatric use | Not recommended for use in children due to lack of safety and efficacy data. |
| Geriatric use | Initial dose: 1 tablet (chlordiazepoxide 5 mg / clinidium bromide 2.5 mg) orally 2 times daily; increase cautiously. Avoid use in frail elderly due to anticholinergic effects and fall risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MENRIUM 5-4 (MENRIUM 5-4).
| Breastfeeding | Chlordiazepoxide and its metabolites are excreted into breast milk. Estimated M/P ratio for chlordiazepoxide is 0.1–0.2. Breastfeeding is not recommended due to potential neonatal sedation, poor feeding, and withdrawal. Estriol is also excreted in milk and may suppress lactation. |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects and congenital heart malformations due to chlordiazepoxide (benzodiazepine) exposure. Second and third trimesters: Risk of fetal benzodiazepine syndrome, including hypotonia, respiratory depression, and withdrawal symptoms in neonates. The estrogen component (estriol) may cause feminization of male fetuses and virilization of female fetuses if high doses are used. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to chlordiazepoxide, clidinium, or any component","Narrow-angle glaucoma","Obstructive uropathy","Myasthenia gravis","Concurrent use with opioids (due to additive CNS depression)"]
| Precautions | ["Risk of dependence and withdrawal reactions with prolonged use","May impair cognitive and motor functions","Caution in elderly, debilitated patients, and those with hepatic or renal impairment","Concomitant use with opioids may cause profound sedation, respiratory depression, coma, and death"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, liver function, and signs of fluid retention. Fetal ultrasound for anatomy and growth in second trimester. Nonstress test or biophysical profile in third trimester. Monitor neonate for respiratory depression, hypotonia, and withdrawal symptoms (irritability, tremors) for 48–72 hours postpartum. |
| Fertility Effects | Chlordiazepoxide may impair fertility in males and females due to effects on hormone regulation (elevated prolactin, menstrual irregularities, decreased libido). Estriol, as an estrogen, may suppress ovulation and affect endometrial receptivity. |